Full Press Release Details
Technologies Announces Results of Annual Meeting
Lyon, France - June 25, 2010- Flamel Technologies S.A.
today announced the results of its annual meeting held on June 25,
2010. The election of each member of the Board of Directors of the
Company for a further one-year term was approved by holders of more than 98% of
the Company's shares. Each additional resolution proposed favorably
by management at the meeting was approved overwhelmingly.
consequence, shareholders re-elected Flamel's Board of Directors. Mr.
Elie Vannier, former
Senior Advisor and Operating Partner at Oaktree Capital Management, will
continue to serve as the Company's non-Executive Chairman. Also
re-elected to the Company's Board of Directors were: Mr. Lodewijk J.R. deVink,
former Chairman and Chief Executive Officer of Warner Lambert; Dr.Frank Fildes,
former Senior Vice President: Head of Global Development for AstraZeneca; Mr.
Frederic Lemoine, Chairman of the Executive Board of Wendel, Mr. John
Vogelstein, former President of Warburg Pincus; and Mr. Stephen H. Willard,
Flamel's Chief Executive Officer.
pleased to have the continued support of our shareholders," said Mr. Elie
Vannier, non-Executive Chairman of Flamel. "Flamel has expanded its
base of partnerships with leading pharmaceutical companies over the past
year. We now are working with eight of the top twenty-five
pharmaceutical companies in the world on projects that involve both novel and
already-marketed molecules. Our scientists have
made important advances on both the Medusa and Micropump technology
platforms. The diversified pipeline of projects we are pursuing is
advancing strongly and we are well-positioned to leverage the advantages that
both platforms bring to our partners with respect to safety and efficacy, as
well as greater convenience for patients and their caregivers. As a
result, we believe in the coming year we will achieve important milestones with
our partners and deliver strong growth to our shareholders."
Technologies, S.A. is a biopharmaceutical company principally engaged in the
development of two unique polymer-based delivery technologies for medical
applications. Micropump is a controlled release and taste-masking technology for
the oral administration of small molecule drugs. Flamel's Medusa technology is
designed to deliver controlled-release formulations of therapeutic proteins,
peptides, and other molecules.
Marlio, Director of Strategic Planning and Investor Relations
document contains "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including certain plans, expectations,
goals and projections regarding financial results, product developments and
technology platforms. All statements that are not clearly historical
in nature are forward-looking, and the words "anticipate," "assume," "believe,"
"expect," "estimate," "plan," will," and similar expressions are generally
intended to identify forward-looking statements. All forward-looking
statements involve risks, uncertainties and contingencies, many of which are
beyond our control, that could cause actual results to differ materially from
those contemplated in such forward-looking statements. These risks include risks
that products in the development stage may not achieve scientific objectives or
milestones or meet stringent regulatory requirements, uncertainties regarding
market acceptance of products in development, the impact of competitive products
and pricing, and the risks associated with Flamel's reliance on outside parties
and key strategic alliances. These and other risks are described more
fully in Flamel's Annual Report on the Securities and Exchange Commission Form
20-F for the year ended December 31, 2009. All forward-looking
statements included in this release are based on information available at the
time of the release. We undertake no obligation to update or alter
our forward-looking statements as a result of new information, future events or